News Briefs

Azura Ophthalmics nets $20m

Azura Ophthalmics Ltd, an Israeli developer of therapies for Meibomian gland dysfunction and related eye diseases, has raised $20 million in financing.

Iris Dorbian

22 October 2020

Azura Ophthalmics Ltd, an Israeli developer of therapies for Meibomian gland dysfunction and related eye diseases, has raised $20 million in financing. The investors included OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund and Ganot Capital.

Source: Press Release

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Nearly there!

Share this:

Register now

Login

Sign in to your account

Nearly there!

We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there.